X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The acquisition of ViaCyte provides Vertex with complementary assets including VC-02, and technologies including additional human stem cell lines, intellectual property around stem cell differentiation, and GMP manufacturing facilities for cell-based therapies.
Lead Product(s): VC-02
Therapeutic Area: Endocrinology Product Name: VC-02
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Vertex Pharmaceuticals
Deal Size: $320.0 million Upfront Cash: $320.0 million
Deal Type: Acquisition July 11, 2022
Details:
The Company is currently advancing a Phase II clinical study on its product candidate PEC-Encap. PEC-Encap (VC-01) is drug-device combination, where PEC-01 cells are loaded into an Encaptra drug delivery System.
Lead Product(s): Encapsulated Pancreatic Islet Precursor Cells
Therapeutic Area: Endocrinology Product Name: PEC-Encap
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Bain Capital Life Sciences
Deal Size: $115.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing June 09, 2021
Details:
VC-02 is designed to enable production of both insulin and glucagon to modulate blood glucose, improve time in range, and ameliorate or prevent complications associated with type 1 diabetes. Phase 2 clinical studies to evaluate the safety and efficacy of VC-02 are ongoing.
Lead Product(s): PEC-01 Cell
Therapeutic Area: Endocrinology Product Name: VC-02
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2021
Details:
Parties have signed an agreement covering the next phase of their ongoing collaboration focused on the development of ViaCyte's Encaptra® Cell Delivery System enabled by proprietary Gore advanced material technologies.
Lead Product(s): Stem cell-derived pancreatic islet cell progenitors
Therapeutic Area: Endocrinology Product Name: PEC-Encap
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: W. L. Gore & Associates
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 05, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
